The Bull Case For Moderna (MRNA) Could Change Following New Data On Its Personalized Cancer Vaccine
Simply Wall St
Last updated: June 15, 2026
Moderna is presenting its mRNA platform's progress, including its influenza vaccine regulatory filings and personalized cancer vaccine program with Merck, which is central to its "second act" narrative. Investors are assessing the platform's durability beyond COVID, with ongoing patent disputes adding another layer of complexity.
- Moderna showcased advancements at the Goldman Sachs Healthcare Conference, focusing on its mRNA platform. Key highlights include regulatory progress for its influenza vaccine and encouraging data from its personalized cancer vaccine (mRNA 4157) with Merck in advanced melanoma, used in combination with Keytruda. This cancer vaccine program is seen as critical for reducing Moderna's reliance on its COVID and RSV franchises.
- The company's broader strategy involves expanding its infectious disease ambitions and building a more durable portfolio. However, near-term catalysts remain focused on late-stage cancer and flu vaccine readouts, while a significant risk lies in whether new vaccines and oncology programs can scale effectively to stabilize cash flows.
- Investor sentiment is influenced by projections of substantial revenue and earnings growth by 2029, requiring significant annual revenue increases. Despite these optimistic forecasts, some analysts have held more cautious views on revenue growth and profitability.
- The text also notes that ongoing legal and patent disputes could impact the ultimate financial success of Moderna's ventures. The article emphasizes the importance of individual investor research, offering resources like a fundamental analysis report and lists of other potentially promising stocks in healthcare and energy sectors.
